dual glp 1 glucagon receptor agonists Discovery of Biased Dual-Agonists of Glucagon-Like Peptide and Receptors through Mutation of a Conserved Aspartate Frontiers | GLP−1 receptor agonists
Description
No funding was received for this research

Introduction Glucagon as an Anti-Obesity Agent Obesity is a leading cause of global morbidity and death

Front Endocrinol (Lausanne) 2019;10:260

These examples underscore the potential for GLP-1 RAs to address a wider range of health challenges in the future

Regional Analysis North America is leading the GLP-1 Receptor Agonist Market North America dominated the market with the highest revenue share of 49.7% owing to the high prevalence of both type 2 diabetes and obesity, coupled with a well-established healthcare infrastructure and favorable reimbursement policies

Compr Physiol